Frank M Armstrong insider trades: Juniper Pharmaceuticals (JNP) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frank reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 23, 2016 | JNP | ↑ Buy | 1,623 | $6.16 | $10K | Direct | Aug 24, 2016 (1d) |
| Jun 15, 2015 | JNP | ↑ Buy | 1,255 | $7.95 | $10K | Direct | Jun 16, 2015 (1d) |
| May 1, 2008 | CRGN | ↓ Sell | 35,000 | $0.91 | $32K | Direct | May 2, 2008 (1d) |
| Feb 11, 2008 | CRGN | ↓ Sell | 23,000 | $0.73 | $17K | Direct | Feb 12, 2008 (1d) |
| Aug 10, 2007 | CRGN | ↑ Buy | 3,400 | $1.33 | $5K | Direct | Aug 14, 2007 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Frank M Armstrong's insider trades
Frank M Armstrong is a director at Juniper Pharmaceuticals (JNP). Since Aug 10, 2007, Frank has reported 3 open-market purchases worth $25K and 2 sales worth $49K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JNP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.